Top Markets
Coin of the day
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Limited

ASLN
株式のランク #37031
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the... ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions. The company is involved in a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., aimed at pioneering immuno-oncology therapeutics that target the AhR pathway. Furthermore, ASLAN maintains partnerships with various entities, including Almirall, Array BioPharma, and CSL Limited. Established in 2010, the company's headquarters are located in Singapore.
株価
$0.6
最終同期: 2024-08-14
時価総額
$2.09M
変化(1日)
0.00%
変化(1年)
0.00%
SG
取引 ASLAN Pharmaceuticals Limited (ASLN)

カテゴリー

ASLAN Pharmaceuticals Limited(ASLN)の利益
Mar 2024 時点の利益 TTM: $-34.90M
ASLAN Pharmaceuticals Limited の最新の財務報告によると、同社の現在の利益は $-34.90M です。2022 年には $-51.28M の利益を上げ、これは 2021 年の利益 $-31.59M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
ASLAN Pharmaceuticals Limited の利益の推移(2014 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-34.90M -20.84%
2023 $-44.09M -14.03%
2022 $-51.28M 62.34%
2021 $-31.59M 86.14%
2020 $-16.97M -63.63%
2019 $-46.66M 10.64%
2018 $-42.17M 3.58%
2017 $-40.71M 352.17%
2016 $-9.00M -32.43%
2015 $-13.33M 80.95%
2014 $-7.36M 0.00%
同業他社の利益
企業 利益 利益の差
$5.27B -15,214.03%
US
$1.95B -5,689.14%
NL
- -
CH
- -
KR
$3.01B -8,712.20%
BE